Blog
Examine exhibits efficacy and security of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian most cancers
04
Jun
Jun
Up to date dose growth information of the part I STRO-002-GM1 examine have been introduced at the moment by Ana Oaknin, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Gynecological Malignancies Group, on the bottom on the 2023 Annual Assembly of the American Society of Medical Oncology (ASCO), 2-6 June in Chicago, USA. […]